There is currently no effective therapy for patients with advanced HLRCC-associated papillary renal cell carcinoma. Treatment with bevacizumab and erlotinib resulted in a confirmed response of 72% in ...

Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) is a rare, autosomal dominant syndrome characterised by the development of cutaneous and uterine leiomyomas alongside an aggressive form of ...

A study from the University of Michigan Health Rogel Cancer Center and Department of Pathology shows that further testing in renal cell carcinoma with an overexpression of gene TRIM63 could uncover a ...

Mia Hamant, the University of Washington’s (UW) star goalkeeper, died at the age of 21 from a rare kidney cancer, the school ...

Merck and Eisai report Phase 3 results showing Welireg plus Lenvima significantly improved progression-free survival in advanced kidney cancer.

Immunotherapy with immune checkpoint inhibitors is standard first-line treatment for advanced renal cell carcinoma (RCC), but not every patient responds.